Dr. Olga Kubassova, CEO of IAG, video interview on scienceboard.net
The CEO of IAG, Dr. Olga Kubassova, was interviewed by The Science Advisory Board and discussed:
- Career paths in industry for women in science
- Experiences and tips for launching a start-up in science
Watch the interview here: https://www.scienceboard.net/
About The Science Advisory Board
The Science Advisory Board is the source for discovery and development in the life sciences.
Our mission is to be a catalyst for future breakthroughs in the life sciences.
We provide a channel for researchers, professionals, trainees, and advocates to keep a thumb on the pulse of life science and biopharmaceutical news and trends. Our communities are designed to feature the latest news in research and exclusive insights into emergent topics. Simply visit our homepage to view the latest news.
Subscribers and Insiders get curated content delivered directly to their inbox on a regular basis, making it easy to keep tabs on developments in the areas of science that they care about.
The Science Advisory Board was established in 1997. It is an expert network of scientists immersed in biological research, drug discovery, and biopharmaceutical production. Members share their knowledge and experience with the community, advise and consult leading life science companies, and earn rewards for their engagement.
To contribute to studies and influence the next generation of science, please become a full member of The Science Advisory Board.
About Olga Kubassova
Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK.
Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, an imaging expert company. She started IAG straight after her PhD with an idea to bring the best of mathematics and computer science to optimize clinical development process while using imaging derived biomarkers to reliably and objectively assess efficacy of a novel drug.
Today IAG is a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Since completing her PhD research in the area of MRI algorithm development for musculoskeletal disorders, Olga has been a significant contributor to the development of MRI as a clinical research and diagnostic tool in rheumatoid arthritis, osteoarthritis and other inflammatory joint diseases. She has co-authored over 60 articles, 7 book chapters and a number of abstracts that have built a significant evidence base for the medical imaging as a sensitive and objective biomarker for the assessment of various diseases and as an early measure of efficacy of new drugs. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals.
Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
About IAG, Image Analysis Group
Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. https://www.ia-grp.com